Michael Gibbons

Has grant

Honorary Associate Clinical Professor

University of Exeter

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Gibbons is an Honorary Associate Clinical Professor at the University of Exeter, UK. His research focuses on interstitial lung disease, pulmonary fibrosis, and the long-term health outcomes following COVID-19 hospitalizations. Recent articles include studies on home monitoring protocols in interstitial lung disease and the effects of Bacille Calmette-Guérin vaccination on immune responses to COVID-19.

Recent Grants

Grant: Close

Examining the role of the human airway in shaping macrophage anti-fungal responses which mediate severe asthma

Open Date: 2023-09-01

Close Date: 2026-09-01

Grant: Close

Exploring the application of machine learning to characterise the driving mechanisms and predict the progression of fibrotic ILD (PREDICT-ILD)

Open Date: 2022-10-01

Close Date: 2025-10-01

Grant: Close

STARSHIP I: Study of Telomeres and Role of Sex Hormones in Pulmonary Fibrosis Stage I: an exploratory study

Open Date: 2022-06-01

Close Date: 2024-06-01

Grant: Close

Exploration of mitochondrial-targeted hydrogen sulfide donors as novel therapeutics for fibroproliferative lung disease

Open Date: 2021-06-01

Close Date: 2024-06-01

Grant: Close

What is the clinical effectiveness and cost-effectiveness of nebulised saline in patients with chronic obstructive pulmonary disease? (MucAct COPD Trial)

Open Date: 2020-04-01

Close Date: 2025-04-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (73)

Nazrul Islam

Associate Professor of Epidemiology and Medical Statistics

University of Southampton

UNITED KINGDOM

Michael Gibbons

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study

Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study

A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease

Home Monitoring in Interstitial Lung Disease: Protocol for a Real-World Observational Study

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.

Nerandomilast in Patients with Progressive Pulmonary Fibrosis.

Body composition, maximal fitness, and submaximal exercise function in people with interstitial lung disease.

Effect of Bacille Calmette-Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination.

Cognitive and psychiatric symptom trajectories 2-3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK.

Research priorities for progressive pulmonary fibrosis in the UK

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study.

Interstitial Lung Disease and Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study

Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study.

Validity and repeatability of cardiopulmonary exercise testing in interstitial lung disease

Residual Lung Abnormalities Following COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID Study.

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.

Collaborators (73)

Nazrul Islam

Susanna Dunachie

Roger Thompson

Jonathan Heeney

Davies Adeloye

Paul Moss

Michael Marks

Antonia Ho

Kay Por Yip

Shaney Barratt

Amy W Chung

Brian Willett

Nazir I Lone

Neil Hanley

Louise MacGillivray

Hamish McAuley

Nigel D. Hart

Mark Halling-Brown

Chris Scotton

Giles Dixon

Cherie Armour

Pilar Rivera-Ortega

Luke Daines

Nazia Chaudhuri

Petros Andrikopoulos

Julie Whitney

Elizabeth Sage

John Busby

Jon Hazeldine

Laura Merson

Tassos Grammatikopoulos

Gerry McCann

Charlotte Bolton

Ryan Thwaites

Timothy Wallis

Paul Dark

Karen Piper Hanley

Effrossyni Gkrania-Klotsas

Rachel Upthegrove

Vicky Kamwa

Joby Cole

Laura Fabbri

Manish Patel

Natalie Stevens

Catherine Atkin

Neil Greening

Michael Crooks

Wenna Lee

Stephen P. McAdoo

Manish Pareek

Alex Horsley

Neil French